Background {#Sec1}
==========

Neuromuscular diseases (NMD) include disorders affecting the anterior horn cells, peripheral nerves, neuromuscular junction and muscles, are often progressive and exhibit a wide range of impairment and disability in affected individuals. Relatively rare, in children these diseases include spinal muscular atrophy (SMA; 1 in 10--11,000) \[[@CR1]\], Charcot-Marie-Tooth disease (CMT; 1 in 2.5--10,000) \[[@CR2]\] and Duchenne muscular dystrophy (DMD; 1 in 3.5--10,0000) \[[@CR3]\]. Gait and functional ambulation are important markers of disease and disability in paediatric NMD. It has been proposed that gait velocity or self-selected walking speed is the 6th vital sign of human function and is a predictor of overall health and disability \[[@CR4], [@CR5]\]. Yet, human gait is a complex activity and gait speed alone does not reflect all contributing factors and influences on gait \[[@CR4], [@CR5]\]. Functional ambulation relates gait function and speed to mobility-related activities of daily living in a person's own environment \[[@CR6]\]. Thus, the assessment of gait and functional ambulation in paediatric NMD must take in to consideration the many constructs that contribute to these complex tasks, including individual impairments, the task required, and the environment in which these are performed.

Weakness is the primary impairment in NMD, often presenting in childhood and adversely affecting gait and functional ambulation. Additionally, muscle tightness, contracture, musculoskeletal deformities, poor standing balance and reduced endurance, all arising from weakness, affect functional ambulatory tasks such as standing and walking. Patterns of weakness differ depending on the NMD, some affecting more proximal muscles (e.g. DMD) and others more distal muscles (e.g. CMT). For the majority of NMD of childhood, disease is progressive leading to increasing weakness and disability across the lifespan. The degree of disability in childhood NMD is variable ranging from children who are extremely weak and unable to sit (e.g. SMA type 1) to those with milder weakness who remain ambulant, albeit with gait difficulties including foot drop, poor balance and reduced gait speed (e.g. CMT, SMA type 3 and ambulant boys with DMD).

Gait dysfunction has important implications for function in everyday life. Ambulant children with NMD, commonly report problems with walking, poor balance, frequent trips and falls, increased fatigue and difficulty keeping up with peers \[[@CR7]--[@CR11]\]. In this context, it is useful to consider the assessment of gait and functional ambulation in ambulant children with NMD in terms of the International Classification of Function, Health and Disability (ICF) \[[@CR12]\] (Fig. [1](#Fig1){ref-type="fig"}). Gait speed is an indicator of impairment. However, a clinically meaningful assessment also needs to consider limitations to the child's activities, restrictions to participation, environmental and intrinsic personal factors. Activity limitations may include difficulty walking longer distances; problems with balance may affect steadiness and safety when walking; and ambulatory performance may be affected by changes in environmental conditions, for example walking over uneven ground or up and down steps. The use of gait or mobility aids will also affect function and low walking confidence or fear of falling may restrict participation opportunities. Assessments of functional ambulation need to take into account all of these factors. There is no recognised single assessment tool of functional ambulation that encompasses all factors. However, there are several clinical assessments that collectively illustrate the effect of disease and disability on gait and function in children with NMD. The aim of this paper is to review assessments of gait and functional ambulation in paediatric NMD. Fig. 1Paediatric neuromuscular disease as it relates to the ICF -- factors relating to gait and functional ambulation (bold)

Method {#Sec2}
======

This narrative review considered the literature relating to gait and functional ambulation in children and adolescents with neuromuscular disease. Literature was searched in Ovid Medline, Embase and PubMed from 1946 up to and including October 2019. Keywords and search terms included gait, walk\*, ambul\*, locomotion, functional ambul\*, paed\*, pediatr\*, child\*, adoles\*, neuromuscular disease, Duchenne and Becker muscular dystrophy, Charcot-Marie-Tooth disease, peripheral neuropathy not diabetes, spinal muscular atrophy, myopathy, Pompe, myotonic dystrophy, collagen VI disorders, fascioscapulohumeral dystrophy or FSHD. Only full-text human studies in English were considered (see [Supplementary material](#MOESM1){ref-type="media"} for example of search strategy). Additionally, hand searching of reference lists and conference abstracts was undertaken to ensure relevant publications were included. Exclusion criteria included studies of non-ambulant participants, primary studies of physical activity and activity monitoring that did not include assessments of gait or functional ambulation, and studies comprised primarily of adults (aged \> 18 years).

Results and discussion {#Sec3}
======================

Studies included {#Sec4}
----------------

Review of the literature resulted in 52 papers describing gait and functional ambulation in over eight neuromuscular diseases of childhood including CMT (15 papers), Becker and Duchenne muscular dystrophies (B/DMD) (21 papers), SMA (7 papers), congenital myotonic dystrophy (CMD) (2 papers), fascioscapulohumeral dystrophy (FSHD) (1 paper), Pompe disease (1 paper), collagen VI disorders (1 paper) and other mixed cohorts (4 papers) (Table [1](#Tab1){ref-type="table"}). Two papers were systematic reviews of gait in CMT \[[@CR18]\] and DMD \[[@CR28]\]. Several papers described the same or similar cohorts, either cross-sectional and longitudinal studies \[[@CR11], [@CR16], [@CR20], [@CR21], [@CR34], [@CR35], [@CR42]\] or a descriptive papers of a randomised controlled trial (RCT) \[[@CR24], [@CR25], [@CR38], [@CR39]\]. The median age of participants in the studies was 9.0 years and sample sizes ranged from 4 to 520. Some studies included adult participants and were included despite the lack of age-related sub-analysis \[[@CR9], [@CR10], [@CR26], [@CR36], [@CR48]--[@CR52], [@CR56], [@CR57], [@CR60]\] or if there were no paediatric studies in a specific disease \[[@CR55]\]. Table 1Review papers including disease, author, study type, sample age and size, outcome measures and main findingsDiseaseStudy type\
AuthorSample sizeAge\
years\
mean (SD)Outcome measuresGait speed\
m/s\
mean (SD)6MWD\
m\
mean (SD)10 m walk/run\
s\
mean (SD)Other assessmentsCMTCross-sectional, observationalEstilow et al. 2019 \[[@CR13]\]CMT *n* = 52010.9 (4.4)Balance (BOT-2)**↓ balance**Mean (SD)z-score − 3.25 (2.9)Cross-sectional, case-controlled observational Kennedy et al. 2019 \[[@CR14]\]CMT *n* = 50TD *n* = 50CMT 12.5 (3.9)TD 12.5 (3.9)6MWTBalance (BOT-2)Walk-12**↓ 6MWD**CMT 507.7 (137.3)TD 643.3 (75.6);*p* \< 0.001Norm to heightCMT 341.9 (95.7)TD 429.4 (56.0);*p* \< 0.001**↓ balance** (BOT-2 /37) median (IQR)CMT 19 (9)TD 32 (3)*p* \< 0.001**Walk-12** mean score **24.7% (SD 19) 95% CI \[19.3, 30.2\]***n* = 49Longitudinal observational Baptista et al. 2019 \[[@CR15]\]CMT *n* = 40TD *n* = 49CMT 11.45 (3.50)TD 10.62 (3.10)10 m walk test(baseline)**Slower 10 m walk**Median (25th; 75th)CMT 7.90 (6.67;8.92)TD 7.25 (5.60; 8.56);*p* ≤ 0.05Cross-sectional, case-controlled observational Kennedy et al. 2018 \[[@CR11]\] ^b^1CMT *n* = 30TD *n* = 30CMT 11.5 (3.7)TD 11.5 (3.7)Gait speed6MWT10 m walk/run (*n* = 26)Balance (BOT-2)**Slower speed**CMT 1.19 (0.16)TD 1.32 (0.14);*p* \< 0.001**↓ 6MWD**CMT 557 (73)TD 615 (71);*p* \< 0.001**Slower 10 m walk/run**CMT 3.8 (1.0)TD 2.9 (0.3);*p* \< 0.001**↓ balance** (BOT-2 /37) Median (IQR)CMT 25.5 (4--34)TD 32 (26--35)*p* \< 0.001Longitudinal cohort Kennedy et al. 2017 \[[@CR16]\] ^b^1CMT *n* = 27Baseline 11.1 (3.7)12 months 12.2 (3.7)Gait speed non−/norm6MWT non−/normBalance (BOT-2)Functional mobility scale (FMS)**Slower norm speed over 12 months**Baseline 1.18 (0.16)12 months 1.15 (0.14);*p* = 0.22Baseline 0.43 (0.07)12 months 0.41 (0.05); *p* = 0.04**↓ norm 6MWD over 12 months**Baseline 556 (73.7)12 months 555 (80.2);*p* = 0.91Baseline 720 (117)12 months 690 (121); *p* = 0.006**No change in balance over 12 months** (BOT-2 /37)Baseline 22.6 (9.4)12 months 23.3 (8.7)*p* = 0.76**FMS 78% reported reduced ambulatory function**Cross-sectional, observational cohortCornett et al. (2016) \[[@CR17]\]CMT *n* = 52010.9 (4.4)6MWT**↓ 6MWD in CMT genotypes**6MWD z-scores reduced in CMT2A, CMT1B, CMT4C compared with CMT1A and CMTX1;*p* \< 0.056MWD z-scores reduced in CMT2A and CMT4C compared with CMT1B; *p* \< 0.05Systematic reviewKennedy et al. (2016) \[[@CR18]\]7 eligible studiesMean 13Range 2--52Gait speed**Slower speed**Range 0.50--1.25Cross-sectional, observationalOunpuu et al. (2013) \[[@CR19]\]CMT *n* = 33TD databaseCMT 11.9 (3.6)TD 12.0 (3.0)Gait speed**Slower speed dependent on gait dysfunction**CMT toe walker 1.17 \[0.21\]CMT "typical" 1.11 \[0.16\]^a^CMT foot drop 1.03 \[0.21\]^a^TD control 1.27 \[0.11\];*p* \< 0.001 ^a^ compared with TDLongitudinal Ferrarin et al. (2013) \[[@CR20]\] ^b^2CMT *n* = 1613.2 (2.9)Gait speed**Non-significant changes in speed with large inter-subject variability**Cross-sectional, case-controlled observationalFerrarin et al. (2012) \[[@CR21]\] ^b^2CMT *n* = 21TD *n* = 18CMT 11.9 (2.8) yoTD 11.0 (3.3) yoGait speed**Slower norm speed**CMT1A foot drop and push-off deficit 69 \[9\]TD 77 \[7\];*p* \< 0.05Norm to heightCross-sectional observationalPagliano et al. (2011) \[[@CR22]\]*n* = 2111.9 (2.8) range 6--17Walk-12**Walk-12Mean 12.4% (SD 9.5) Range 0--33**RCTRose et al. (2010) \[[@CR23]\] ^a^CMT treatment group *n* = 15CMT placebo group *n* = 15CMT treatment 10 \[4\] yoCMT placebo 11 \[3\] yoGait speedCMT treatment group 0.50 \[0.10\]CMT placebo group0.60 \[0.50\]RCTBurns et al. (2009a) \[[@CR24]\] ^b^3*n* = 81\[*n* = 53 for gait data; *n* = 65 for 6MWT data\]8.3 (3.5)Gait speed6MWTBaselineCMT treatment group 1.19 (0.16)CMT placebo group 1.24 (0.19)BaselineCMT treatment group 519 (86)CMT placebo group521 (98)Cross-sectional, observationalBurns et al. (2009b) \[[@CR25]\] ^b^3*n* = 81\[*n* = 53 for gait data; *n* = 65 for 6MWT data\]8.3 (3.5)Gait speed6MWTCMT 2--6 yo 1.13 (0.25)CMT 7--11 yo 1.25 (0.12)CMT 12--16 yo 1.23 (0.14)CMT 2--6 yo 494.3 (70.6) 385--640CMT 7--11 yo 526.8 (83.1) 250--640CMT 12--16 yo 518.7 (150.2) 110--710Cross-sectional, observationalNewman et al. (2007) \[[@CR26]\] ^a^*n* = 16TD database *n* = 40CMT 20.1 (13)TD 18.4 (8.5)Gait speed**Slower speed**CMT 1.12 (0.17)TD controls 1.31 (0.13);*p* \< 0.001DMDLongitudinalFowler et al. (2018) \[[@CR27]\]*n* = 427.9 (2.9)Range 4.1--16.110 m walk/run testStepWatch Activity monitoringBaseline speed 1.71 (0.68) m/s as measured by 10 m walk/runBaseline 5.85 s derived from reported gait speed**Significant ↓ average strides per day with ↑ age**; per age group average strides per day ↑ for 4-7yo, plateau for 8-10yo and ↓ \>10yoSystematic review of gaitGoudriaan et al. (2018) \[[@CR28]\]9 eligible studiesGait speed calculated from 6 studies**Slower speed compared to TD**Standardised mean difference (effect size) ranging from 1.26 to 3.20RCTVictor et al. (2017) \[[@CR29]\]*n* = 3319.6 (1.92)6MWT10 m walk/runBaseline329.6 (55.47)Baseline6.8 (1.97)Cross-sectional observationalcase controlledAlfano et al. (2017) \[[@CR30]\]DMD *n* = 72TD *n* = 599DMD range 4--12TD range 4--14100 m timed test**Slower timed 100 m across all ages compared to TD;** *p* \< 0.01**DMD times improve up to 6 years and then decline from 7 years**Cross-sectional, observational case controlledRopars et al. (2016) \[[@CR31]\]DMD *n* = 16TD *n* = 15DMD 8.67 (2.04)TD 9.39 (2.21)Gait speed**Slower speed compared to TD**DMD 0.78 (0.18)TD 1.21 (0.13);*p* \< 0.001Cross-sectional observational case-controlledDavidson et al. (2015) \[[@CR32]\]DMD *n* = 16TD *n* = 13DMD 9.0 (2.1)TD 9.0 (2.4)6MWTStepWatch Activity monitoring**↓ 6MWD compared to TD**DMD 387 (86)TD 598 (63);*p* \< 0.005**↓ steps and high activity time and ↑ inactive time compared to TD**StepsDMD 5138 (2500)TD 7239 (2621);*p* = 0.044High activity timeDMD 25 (17)TD 53 (34) min*p* = 0.018Inactive timeDMD 1103 (134) minTD 1016 \[[@CR33]\] min;*p* = 0.036Longitudinal observationalPane et al. (2014) \[[@CR34]\] ^b^4*n* = 96Baseline8.3 (2.3)6MWT**↓ 6MWD 3 years**− 15.8 (77.3) at 12 months, − 58.9 (125.7) at 24 months and − 104.22 (146.2) at 36 monthsLongitudinal observationalMazzone et al. (2013) \[[@CR35]\] ^b^4*n* = 1138.24.1--17.06MWT**↓ 6MWD 2 years−** 22.7 (SD 81.0) 1st year − 64.7 (SD 123.1) 2nd yearLongitudinal observationalHenricson et al. (2013a) \[[@CR36]\]*n* = 340Baseline range2--2810 m walk/run**Slower 10 m walk/run with ↑ age**No participant aged \> 18 years able to walkLongitudinal observational, case-controlledHenricson et al. (2013b) \[[@CR37]\]DMD *n* = 24TD *n* = 361 yearDMD *n* = 13TD *n* = 18DMD 7.9 (2.3)TD 8.7 (2.6)6MWT10 m walk/run**Baseline ↓ 6MWD**DMD 369.5 (79.3)TD 613.3 (73.6) *p* \< 0.001**MCID 26.4 m1 year change DMD \> MCID**DMD − 53.67 (SE 25.96) *p* = 0.027TD 16.5 (SE 11.46)**Baseline ↓time**DMD 1.68 (0.56)TD 3.32 (0.36)*p* \< 0.001**MCID 0.19 s1 year change DMD \> MCID**DMD − 0.25 (SE 0.68) *p* = 0.007TD 0.33 (SE 0.07) *p* \< 0.001Observational study McDonald et al. (2013a) \[[@CR38]\]*n* = 1748.5 (2.6)6MWT10 m walk/run**358 (95)MCID 28.5--31.7 m7.4 (4.3)MCID 2.3--1.4 s**Longitudinal observational studyMcDonald et al. (2013b) \[[@CR39]\]*n* = 578.3 (2.33)6MWT10 m walk/run**↓ 6MWD 48 weeks**Baseline 361.1 (87.5)Week 48,317.4 (152.3)**Slower 10 m walk/run with ↑ age**Baseline\< 7yo 4.8 (0.86)\> 7yo 7.1 (2.80)Longitudinal observational studyBello et al. (2012) \[[@CR40]\]*n* = 802 genotypesGroup 1 = 57Group 2 = 238.3 (2.7)6MWT**↓ 6MWD 12 months, associated with age** (*r* = − 0.38 *p* = 0.013), **baseline 6MWD** (*r* = 0.73, *p* \< 0.001**) and genotype** (*p* = 0.029)BaselineGp 1368 (86)Gp 2387 (67)12 monthsGp 1360 (98)Gp 2343 (124)Cross-sectional, observational case controlledDoglio et al. (2011) \[[@CR41]\]DMD *n* = 15TD *n* = 9DMD 6.1 (0.7)TD 7.5 (1.2)Gait speed10 m walk**Speed in younger boys with DMD does not differ to TD**DMD 1.06 (0.17)TD 1.07 (0.18)NS**Slower 10 m walk**DMD 4.4 (3.2)TD 3.4 (0.6)*p* \< 0.05Longitudinal observational studyMazzone et al. (2011) \[[@CR42]\] ^b^4*n* = 106(*n* = 100 10 m walk/run)Baseline8.3 (2.3)10 m walk/run6MWT**↓ 6MWD 12 months, \> in older boys**≤ 7 yo − 7.8 (63.9)\> 7 yo − 42.3 (73.9)All − 25.8 (74.3);*p* = 0.01(≤7yo vs \> 7yo)**Slower 10 m walk/run in older boys**≤ 7 yo 0.3 (3.1)\> 7 yo 1.3 (3.5)All 1.0 (3.4)*p* = 0.11 ≤ 7yo vs \>7yoCross-sectional observational studyMazzone et al. (2010) \[[@CR43]\]*n* = 1128.18 (2.3)10 m walk/run6MWTRange 127--560.6Range 3--15Cross-sectional observational case controlledMcDonald et al. (2010) \[[@CR44]\]DMD *n* = 21TD *n* = 34Median \[range\]DMD 8 \[5--12\]TD 9 \[4--12\]6MWT**↓ 6MWD compared to TD**DMD 366 (83)TD 621 (68);*p* \< 0.001Cross-sectional observational case controlledGaudreault et al. (2010) \[[@CR8]\]DMD *n* = 11TD *n* = 14DMD 9.2 (2.6)TD 9.7 (1.9)Gait speed**Slower speed**DMD 0.62 (0.12)TD 1.02 (0.13)*p* \< 0.001Cross-sectional, observational case controlledD'Angelo et al. (2009) \[[@CR45]\]DMD *n* = 21TD *n* = 10DMD 7.0 (2.4)TD 7.4 (1.2)Gait speed**Trend to slower norm speed**DMD 0.81 (0.14)TD 0.90 (0.13)norm to height; NSRCTSkura et al. (2008) \[[@CR46]\]*n* = 15Baseline8.4 (1.46)30 ft timed walk/run testBaseline 30 ft timed run5.6 (1.3)RCTBeenakker et al. (2005) \[[@CR47]\]*n* = 16Baseline6.25 (0.93)Range 5--89 m runBaseline speed 1.78 m/s= 5.06 s over 9 mSMAPilot studyBartels et al. (2019) \[[@CR48]\]*n* = 426.2; range 10--37Endurance shuttle walk test (ESWT)**ESWT feasible measure of fatigability during walking in SMA3**Longitudinal, observationalMontes et al. (2018) \[[@CR10]\]*n* = 7313.5 (12.4) range 2.6--49.16MWTBaseline SMA3a 257.1 (107.3)SMA3b 390.2 (144.0)**Mean rate of change − 7.8 m/year**; *p* = 0.009**Age affects rate of change**\<  6 yrs.: 9.8 m/ year; 6--10 yrs.: − 7.9 m/year; 11--19 yrs.: − 20.8 m/year; \> 20 yres: − 9.7 m/year; *p* = 0.005Cross-sectional, observationalMontes et al. (2014) \[[@CR49]\]*n* = 1031.2; range, 9--496MWT273.4 (45.7); range, 53--492Dunaway et al. (2014) \[[@CR50]\]*n* = 1528.7; range 10--4910 m walk/run6MWTTimed up and go (TUG)362.13 (29.22)7.44 (0.84)TUG12.97 (2.49) s;**Moderate to good correlation between TUG and 10 m walk/run** (*r* = 0.691; *p* = 0.009) **and 6MWT** (*r* = − 0.514; *p* \< 0.05)Longitudinal observational studyMazzone et al. (2013) \[[@CR51]\]^a^*n* = 3814.07 (12.43) 3.4--49.36MWT**No change in 6MWD 12 months**Baseline 294.91 (127)12 months 293.4 (141)Cross-sectional, case controlledMontes et al. (2011) \[[@CR9]\]SMA3 *n* = 9TD *n* = 9224--49 years6MWT**↓ 6MWD**SMA3 343 m (range 267--449)TD 601 m (range 490--733)Cross-sectional observationalMontes et al. (2010) \[[@CR52]\]*n* = 1815.3(13.3)6MWT10 m walk/run288.9 (161.9)**Strong correlation between 6MWT and 10 m walk/run** (*r* = − 0.87; *p* \< 0.0001)Median (25th, 75th %)8.4 (5.4,10.7)CMDCross-sectional observationalHayes et al. (2018) \[[@CR53]\]*n* = 257.76 (3.02) 3.25--13.2210 m self-selected walk speed6MWTStepWatch activity monitoring0.97 (0.26) 0.52--1.36325.23 (109.85)150--604**↓ physical activity**Time inactive, % 80.85 (9.15) Low steps, % 33.19 (13.11) Medium steps, % 51.15 (9.80) High steps, % 16.01 (10.27)Cross-sectional observational case-controlledJohnson et al. (2016) \[[@CR54]\]CMD *n* = 41(6MWT *n* = 33)TD *n* = 29CMD 6.8 (3.3)TD 9.1 (3.1)6MWT**↓ 6MWD**CMD 258.3 m (SD 176)TD 568.3 m (SD 73.2);*p* \< 0.001FSHDObservational test-retest reliability studyEichinger et al. (2017) \[[@CR55]\]^a^*n* = 8649.1 (15.2) 18--846MWT404.3 (123.9); Reliability ICC = 0.99 (*n* = 25)**Minimal detectable change (MDC95) 34.3**Late onset PompeObservational cross-sectionalMcIntosh et al. (2015) \[[@CR56]\]^a^*n* = 22Gender age-matched reference data48.6 (range 13--72)Gait speed6MWT10 m fast walk test1.02 (0.30)**Variable performance ranging from 39.4 to 110% predicted**10 m fast walk1.41 (0.42) m/s = 7.09 sCollagen VILongitudinal observationalMeilleur et al. (2015) \[[@CR57]\]^a^*n* = 32(*n* = 11 for 10 m walk/run and 6MWT)Range 4.8--21.26MWT10 m walk/run338.27 (126.65) 144--60010 m walk8.6 (3.5) 4.0--15.8NMD(mixed)Cross-sectional observationalWitherspoon et al. (2019) \[[@CR58]\] ^c^*n* = 7710.1 ± 2.936MWT2MWT442.1 (121.6)2MWD = 149.8 (40.3) m**Strong correlation 2MWD and 6MWD*r*** **= 0.90,** ***p*** **\< 0.01**Cross-sectional observationalKaya et al. (2015) \[[@CR59]\]*n* = 40DMD = 20PN ^d^ = 20DMD 9.05 (3.1)PN 12.95 (3.3)6MWTTUGDMD 349.70 (77.18)PN 358.85 (75.07)NSTUGDMD 7.79 (1.54) sPN 10.13 (2.63) s*p* \< 0.01Cross-sectional observationalMontes et al. (2013) \[[@CR60]\] ^a\ e^*n* = 11421.3 (range 4--64)6MWT(% predicted of normative reference data)Mean 61.9%DMD/BMD 65.1%SMA 52.0%myasthenia gravis 66.3%GLUT1 deficiency/mitochondrial disorders 63.9%Cross-sectional observationalHoltebekk (2013) \[[@CR61]\] ^f^*n* = 17Median (IQR) 14.2 (3.6)6MWTActivity monitoring SenseWear ArmbandMedian (IQR) 485 (131)Activity monitorModerate physical activityMedian (IQR) 2.4 (1.9) hours/weekday1.1 (3.3) hours/weekend dayMean and standard deviation (SD) unless otherwise stated; IQR = inter-quartile rank; Main findings in boldAbbreviations: *6MWT* six-minute walk test, *6MWD* six-minute walk distance, *BMD* Becker muscular dystrophy, *BOT-2* Bruininks-Oseretsky Test, 2nd Edition, *CMT* Charcot-Marie-Tooth disease, *CMD* Congenital myotonic dystrophy, *DMD* Duchenne muscular dystrophy, *ESWT* Endurance shuttle walk test, *FMS* Functional Mobility Scale, *FSHD* fascioscapulohumeral dystrophy, *LGMD* limb girdle muscular dystrophy, *NMD* neuromuscular disease, *norm* norm, *PN* peripheral neuropathies, *SMA* spinal muscular atrophy^a^Nelson - included adult participants with no sub analysis; McIntosh -- 2 of 22 subjects aged ≤18 years, no sub-analysis; Mazzone - included adult participants with no sub analysis; Eichinger -- one 18-year-old participant, all others adults with no sub-analysis; Meilleur - included adult participants with no sub analysis; Montes - included adult participants with no sub analysis^b^ same data sets^c^Collagen VI-related dystrophy (COL6-RD), laminin alpha 2-related dystrophy (LAMA2-RD), limb-girdle muscular dystrophy (LGMD), and RYR1-related myopathies (RYR1-RM), and other^d^PN = peripheral neuropathies including CMT/hereditary motor and sensory neuropathy (HMSN), motor neuropathy (MN) and polyneuropathy (PNP)^e^Spinal muscular atrophy (*n* = 23), Duchenne/Becker muscular dystrophy (*n* = 29), myasthenia gravis (*n* = 12), or an energy failure syndrome (glucose transporter protein type 1 \[GLUT1\] deficiency/mitochondrial disorders) (*n* = 50)^f^CMT *n* = 4, Congenital myopathy *n* = 2, LGMD 2I *n* = 8, BMD *n* = 1, Unspecified *n* = 2

Assessments of gait and functional ambulation {#Sec5}
---------------------------------------------

Several assessments of gait and functional ambulation in paediatric NMD were identified and discussed in the literature. These included timed function tests, for example the 10 m walk and/or run test \[[@CR62], [@CR63]\], the six-minute walk test (6MWT) \[[@CR64]\] and 100 m timed test \[[@CR30]\]. Tests of dynamic balance in walking, including the balance subset of the Bruininks-Oseretsky Test, 2nd edition (BOT-2) \[[@CR65]\] and the timed up and go (TUG) \[[@CR66]\], were considered due to the impact of balance on gait and function. If studies of gait or functional ambulation included activity monitoring, these were reported as an adjunct to specific assessments of gait, however we did not specifically search for studies of activity monitoring alone. We also included descriptive scales or questionnaires that characterised gait-related function, including the Functional Mobility Scale (FMS) \[[@CR67]\] and the Walk-12 scale \[[@CR68]\].

### Gait speed {#Sec6}

For this review we focused on gait speed in terms of its clinical utility as an indicator of health and disability \[[@CR4], [@CR5]\]. Assessment of gait speed was diverse with a range of reported methodologies including 3-D gait analysis, electronic walkway and timed distance. Typically, gait is assessed at natural self-selected steady walking pace, however some studies reported gait speed as calculated from the 10 m walk/run, usually a fast walk or run test \[[@CR27], [@CR56]\]. Gait speed was described most often in studies of children with CMT (ten of fifteen papers), a reflection of the use of clinical gait analysis in preparation for orthopaedic surgery for the management of foot deformities common in CMT \[[@CR11], [@CR16], [@CR18]--[@CR21], [@CR23]--[@CR26]\]. Children with CMT walked more slowly than their typically developing peers and a decline in gait speed over time was evident when growth was accounted for by normalising gait speed to height or leg length \[[@CR16]\]. Greater disability in children with CMT was reflected in slower gait speed in more severely affected children \[[@CR19]\].

Younger boys (\< 7 years) with DMD did not walk significantly slower than their typically developing peers \[[@CR41], [@CR45]\]. However, boys older than 8 years with DMD were significantly slower than their peers, an indicator of the relentless and degenerative muscle disease \[[@CR8], [@CR31]\]. The study by Doglio et al. (2011) was the only study to normalise gait speed to height when comparing boys with DMD to TD controls. Normalising gait parameters is an important consideration for boys with DMD who are typically treated with corticosteroids, of which growth retardation is a known side-effect. Therefore, steroid-treated boys with DMD tend to be smaller than their age-matched, steroid naïve and non-affected peers \[[@CR69]\]. Normalisation to height and/or leg length is an important to factor when reporting gait speed in paediatric populations \[[@CR70], [@CR71]\].

Gait speed was reported in two other studies in children with CMD \[[@CR53]\] and a mixed aged study of children and adults with late-onset Pompe disease \[[@CR56]\]. Whilst neither study included unaffected controls, the reported gait speed for both cohorts was considerably slower than reported normative reference data \[[@CR72]\].

### Six-minute walk test {#Sec7}

The 6MWT is a valid and reliable standardised test of physical endurance in boys with DMD \[[@CR38]\]. A test of ambulatory capacity, the 6MWT measures distance walked in six minutes. Developed from the American Thoracic Society and FDA-approved 6MWT \[[@CR64]\], the test has been modified for children with NMD with the addition of a safety chaser and standardised verbal encouragement \[[@CR44]\]. The utility of the 6MWT in paediatric NMD clinical research is evident with over half of the studies included in this review reporting its use \[[@CR9]--[@CR11], [@CR14], [@CR16], [@CR17], [@CR24], [@CR25], [@CR29], [@CR32]--[@CR35], [@CR37]--[@CR40], [@CR42]--[@CR44], [@CR50]--[@CR61]\] (Table [1](#Tab1){ref-type="table"}). Typical walkway distances were reported as 25 m however some studies used walkways as short as 10 m \[[@CR24], [@CR25]\]. This may reduce distance walked due to more frequent turns resulting in greater time spent decelerating and less time at a fast walking pace \[[@CR73]\].

Six-minute walk distance (6MWD) is reduced in children and adolescents with NMD when compared to typically developing controls or normative reference data. In boys with DMD and children with SMA type 3 and CMT, 6MWD declines with increasing age, reflecting disease progression and increasing disability \[[@CR10], [@CR16], [@CR34], [@CR35], [@CR37], [@CR39], [@CR40]\]. Normalisation of 6MWD to height or leg length, accounts for linear growth across age groups and in longitudinal studies, and is an important factor when determining the effect of disease on function \[[@CR16]\]. Burns and colleagues (2009), demonstrated a trend to shorter 6MWD in older children \[[@CR25]\]. In a further study over 12 months, normalisation of 6MWD accounting for growth revealed a decline in ambulatory capacity in children with CMT \[[@CR16]\]. Genotype also affects ambulatory capacity in the 6MWT; children with milder subtypes of CMT in a large study of 520 participants, walked further than children with more severe subtypes \[[@CR17]\]. Deterioration in ambulatory capacity over time was also affected by genotype in 80 boys with DMD \[[@CR40]\]. Several studies have reported rates of change, either minimally clinically important difference (MCID) or minimal detectable change (MDC) for 6MWD in different NMD including DMD (MCID 26.4--31.7 m; − 53.67 change over 12 months) \[[@CR37], [@CR38]\], SMA (− 7.9 to − 9.7 m over 12 months) \[[@CR10]\] and FSHD (MDC95 34.3 m) \[[@CR55]\]. Measures of rate of change, MCID or MCD are useful for clinicians when comparing the ambulatory function of the children in their own clinical practice.

### Timed function tests -- 10 m walk/run {#Sec8}

The timed 10 m walk/run is widely used to assess function in NMD and is a sensitive measure of disease progression in ambulant boys with DMD \[[@CR62], [@CR74], [@CR75]\]. In clinical practice, the timed 10 m walk/run is conducted as a fast walk or run dependent on the abilities of the child. However, in the literature there were differences noted between whether the test was conducted as a timed walk \[[@CR15], [@CR41], [@CR56], [@CR57]\] or run, and earlier studies conducted the test over 30 ft or 9 m \[[@CR46], [@CR47]\]. Timed 10 m walk/run was most often reported in boys with DMD \[[@CR27], [@CR29], [@CR36]--[@CR39], [@CR41]--[@CR43], [@CR46], [@CR47]\] reflecting its common use as a predictor of disease in DMD and less frequently in studies of CMT, SMA, Pompe and Collagen VI \[[@CR11], [@CR15], [@CR50], [@CR52], [@CR56], [@CR57]\]. Across all NMDs, 10 m walk/run times were slower compared to controls or reported normative reference ranges. Disease progression in boys with DMD was demonstrated with several studies reporting slower speed over 10 m in boys older than 7 years \[[@CR36], [@CR39], [@CR42]\].

### Other assessments {#Sec9}

Assessments of balance, endurance and alternative distance and timed tests (100 m timed walk and two-minute walk test) were reported less frequently. The balance subset of the Bruininks-Oseretsky Test of Motor Proficiency, 2nd Ed (BOT-2, NCS Pearson, Upper Saddle River, NJ, USA) is a ten-item standardised test of balance in standing and walking \[[@CR65]\]. It is widely used in paediatric CMT having been incorporated into the disease-specific CMT Pediatric Scale (CMTPedS) \[[@CR76]\]. Balance in children with CMT was significantly reduced when compared to age- and gender-matched controls and normative reference data \[[@CR11], [@CR13], [@CR14]\]. However, over 12 months', balance did not significantly deteriorate, indicative of the relatively slow progression of neuropathy in children with CMT \[[@CR16]\]. Reduced balance (BOT-2) was associated with wider base of support and greater step-to-step variability in the gait of children with CMT \[[@CR11]\].

The TUG was reported in two studies and is a valid, reliable and responsive measure of gait-related balance in children with physical disabilities \[[@CR50], [@CR59], [@CR77], [@CR78]\]. It measures the time taken to stand from a seated position, walk 3 m, turn around and return to a seated position. Dunaway and colleagues (2014) demonstrated an association between the TUG, slower 10 m walk/run time and shorter 6MWD in children with SMA type 3 \[[@CR50]\]. In a further study comparing older children with peripheral neuropathies (PN) of mixed origin to younger boys with DMD, TUG times were longer in the children with mixed PN \[[@CR59]\]. The authors attributed the difference between groups to the effects of distal versus proximal weakness patterns, however it may have also been due to the PN group being older and therefore likely to be more affected by their disease. Both the BOT-2 and the TUG are useful assessments of gait-related balance and inform clinical interpretation of the effects of NMD on gait and function.

Alternatives to the 6MWT were reported in two studies. Alfano and colleagues (2017) reported the development and validation of a 100 m timed test in boys with DMD as an assessment of functional ambulatory performance. Their study included the establishment of typically developing normative reference data \[[@CR30]\]. Findings from this study indicated that performance on the 100 m timed test improved up to the age of 7 years before plateauing and declining with increasing age \[[@CR30]\]. This finding is similar to the 10 m walk/run and the 6MWT in boys with DMD and is reflective of disease progression \[[@CR36], [@CR39], [@CR40], [@CR42]\]. A second study in children with mixed NMD, reported a two-minute walk distance (2MWD) derived from the two-minute mark of the standard 6MWT, and found a strong correlation between 2MWD and 6MWD \[[@CR58]\]. Both the 100 m timed test and the 2MWT may offer realistic alternatives to the longer 6MWT, especially in children with behavioural and attentional problems who may find the time and testing constraints of six minutes challenging.

The 6MWT and more recently the 100 m timed test and 2MWT, are all described as tests of physical endurance in paediatric NMD and as surrogate measures of physical fatigue in DMD, SMA and CMT \[[@CR9], [@CR25], [@CR44]\]. Bartels and colleagues (2019) have recently described the concept of fatigability in SMA, that is, "*the inability to perform prolonged repetitive tasks during activities of daily life"*, and have developed a group of endurance tests to assess fatigability \[[@CR48]\]. The Endurance Shuttle Walk Test is a feasible test of endurance in ambulant people with SMA type 3. An externally paced walking task, the objective is to cover 10 m before each beep. The time between repeated beeps decreases, requiring an incremental increase in walking speed. This pilot study is the first report of the Endurance Shuttle Walk test and further studies are required to determine its validity, responsiveness and clinical utility in SMA and paediatric NMD.

The advent of wireless wearable activity monitors allows remote measurement of gait-related physical activity in children with NMD. Several studies have included wearable devices to measure steps and physical activity in DMD, CMD and mixed NMD \[[@CR27], [@CR32], [@CR53], [@CR61]\]. Davidson and colleagues (2015) found that boys with DMD have reduced daily step counts and reduced high activity time, with correspondingly greater inactivity compared to typically developing peers \[[@CR32]\]. In a longitudinal study, Fowler and colleagues (2018) described physical activity levels in boys with DMD following a similar trajectory to timed tests and the 6MWT \[[@CR27]\]. Daily step counts rose up to the age of 8 years, before plateauing and declining from the age of 10 years \[[@CR27]\]. Children with NMD are largely inactive, spending up to 80% of their awake time in sedentary activities and on average only 2 h a day at a moderate intensity of activity \[[@CR53], [@CR61]\]. Whilst we assume neuromuscular weakness contributes to reduced physical activity, it is quite possible that reduced physical activity contributes further to increasing weakness. Lack of physical activity, together with disease-related weakness, is likely to impact gait and function in children with NMD.

### Descriptive measures of gait {#Sec10}

Together with quantitative measures of gait and function, descriptive scales and questionnaires are used to characterise gait and functional ambulation in paediatric NMD. Two such measures reported in this review are the Functional Mobility Scale (FMS) \[[@CR67]\] and the Walk-12 \[[@CR68]\] which have not been widely utilised in paediatric NMD to date.

The Functional Mobility Scale (FMS) is a clinical tool used to classify typical mobility over three distance categories -- 5, 50 and 500 m in children with gait dysfunction \[[@CR67]\]. These distances are commensurate with walking in the home (5 m), between classrooms in the school environment (50 m) and distances required in general community environments (500 m). The scale considers the level of assistance the child requires and a grading from 1 to 6 is applied; where 1 indicates the use of a wheelchair and 6 indicates fully independent walking on all surfaces and terrains, including stairs without use of a rail. One study has described functional mobility in children with CMT \[[@CR16]\]. In this study 78% of the children reported reduced ambulatory function, across one or all distance/environment categories (score \< 6) describing the functional impact of disease. Over 12 months there was little change in FMS scores, in keeping with the slow progression of CMT.

The Walk-12 is a self-reported questionnaire of perceived impact of disease on gait and gait related activities, such as running, using stairs and balance, modified and validated in adults with peripheral neuropathies \[[@CR68], [@CR79]\]. The tool is scored from 0 to 100%, where 0% indicates no impact and 100% indicates a high impact of disease on gait and related activities. In two studies, Walk-12 scores ranged from 12 to 25%, indicating that children with CMT perceived only mild impact of disease on gait and gait-related function \[[@CR14], [@CR22]\]. Interestingly, further examination of answers to individual questions indicated that CMT affected their ability to run (43%), ascend or descend stairs (41%), the speed with which they could walk (31%) and made it more effortful to walk (31%) \[[@CR14]\]. Additionally, over 40% of the children reported moderate to severe limitations to their ability to walk longer distances in their everyday environments.

Clinical implications and future directions {#Sec11}
-------------------------------------------

Gait performance and functional ambulation are biomarkers of disease severity in paediatric NMD, providing a measure of disability. Assessment of gait and functional ambulation are important outcome measures in the toolbox of assessments for clinical research trials and in the clinical setting. With the advent of disease-modifying pharmacological treatments and uptake of physiotherapeutic exercise, younger people, including children with NMD are likely to benefit most from treatments. Therefore, it is important to utilise functional measures specific to children and adolescents to monitor disease progression and treatment efficacy.

There remains a need for further research and development of functional gait outcome measures for paediatric NMD. Limitations including the heterogeneity of the study populations and differences in assessment protocols precluded meta-analysis of these studies. ​As evidence accumulates, a more analytical systematic review may provide additional insights. The disparity of gait assessments in paediatric neuromuscular diseases also suggests that a Delphi survey would be useful in establishing expert consensus on which measures to use. Factors such as the normalization of gait parameters is important when comparing gait across age ranges and longitudinally to account for growth in children and should be standardly applied both clinically and in research. Further development and publication of paediatric normative reference datasets and MCIDs will be a valuable resource for clinicians working in neuromuscular clinics. Qualitative characterisation of gait and functional ambulation with scales or questionnaires enables clinicians to gain an understanding of the effect of disease on the day-to-day lives of children with NMD, beyond the neuromuscular outpatient clinic. The self-reported scales of functional mobility and gait-related activities require validation in paediatric NMD populations to ensure that they provide meaningful information and enable greater uptake by clinicians. Further exploration and utilization of technology for remote and wireless monitoring and measurement of walking in the typical environments of children, including home, school and the community provide greater understanding of the effect of disease on function.

Conclusion {#Sec12}
==========

This narrative review has highlighted clinical measures of gait ranging from gait speed to tests of ambulatory capacity, physical endurance and gait-related balance that can be conducted in clinical and research settings with relative ease. Consideration of environmental factors affecting function including distance requirements necessitated by school and community settings is important when understanding the effect of disease. An individual's perception of the effect of disease on walking and everyday function are important considerations in the clinical setting. Person-centred characterization and assessment of gait dysfunction discussed in this narrative review provides a rich and holistic illustration of disability, and offers genuine outcome measures of potential therapeutic benefits on gait and functional ambulation in paediatric NMD. However, consensus is required amongst experts in paediatric neuromuscular disorders to establish a core set of gait and functional ambulatory assessments that can be used clinically and in research settings.
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